A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2014
At a glance
- Drugs MORAB 028 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Morphotek
- 15 Jul 2014 Status changed from withdrawn prior to enrolment to discontinued as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 08 Oct 2010 New trial record